Tracheomalacia
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
VideregenUK - Leeds
1 program1
Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cellsPhase 1
Catapult TherapeuticsNetherlands - Lelystad
1 program1
Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cellsPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Catapult TherapeuticsCadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
Clinical Trials (1)
Total enrollment: 4 patients across 1 trials
NCT02949414Catapult TherapeuticsCadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells
Start: Sep 2016Est. completion: Sep 20244 patients
Phase 1Suspended
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.